Affimed N.V.

News & Events

Press Releases

In The Media

1. Affimed Announces Receipt of Nasdaq Delisting Notice

   GlobeNewswire MAY 14, 2025 6:45 AM EDT
   MANNHEIM, Germany, May 14, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage...
   READ ARTICLE

2. Affimed Announces Filing for the Opening of Insolvency Proceedings

   GlobeNewswire MAY 13, 2025 8:15 AM EDT
   MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage...
   READ ARTICLE

3. Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

   GlobeNewswire APR 29, 2025 10:00 AM EDT
   An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) wh...
   READ ARTICLE

4. Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual Meeting

   GlobeNewswire APR 23, 2025 10:05 AM EDT
   MANNHEIM, Germany, April 23, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affime...
   READ ARTICLE

5. Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

   GlobeNewswire APR 21, 2025 6:30 AM EDT
   MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-sta...
   READ ARTICLE

6. Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual Meeting

   GlobeNewswire MAR 25, 2025 4:30 PM EDT
   MANNHEIM, Germany, March 25, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-sta...
   READ ARTICLE

7. Affimed to Present at the Leerink Partners Global Healthcare Conference 2025

   GlobeNewswire MAR 3, 2025 6:30 AM EST
   MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affime...
   READ ARTICLE

8. Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)

   GlobeNewswire DEC 17, 2024 6:30 AM EST
   In 33 heavily pretreated NSCLC EGFR wild-type ( EGFR wt) patients the combination of AFM2...
   READ ARTICLE

9. Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

   GlobeNewswire DEC 9, 2024 1:30 PM EST
   AFM28, a bispecific, tetravalent innate cell engager (ICE ® ) targeting CD123 and CD16A,...
   READ ARTICLE

10. Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer

    GlobeNewswire DEC 9, 2024 6:30 AM EST
    MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed...
    READ ARTICLE